Research & Evidence

Dietary Signals is built on evidence-based research from global health organizations, peer-reviewed science, and industry best practices.

Research Highlights → Global Health & Equity →

Our Approach

Global Health, Local Relevance

Dietary Signals is built on the recognition that metabolic health is a global problem, but not a uniform one. The biology of glucose regulation is shared across humanity; access to diagnostics, therapies, and culturally appropriate dietary guidance is not.

Tier 1

Immediate Impact

Personalization, optimization, clinical augmentation

United States & CanadaHigh CGM adoption, strong GLP-1 access, digital health leaders
Western EuropeUK, Germany, Nordics – NICE/EASD governance, reimbursement-driven
India101M+ with diabetes, earlier onset, massive prevention need at scale

Tier 2

Rapid Growth

Scalable prevention, early intervention, cultural adaptation

Latin AmericaBrazil, Mexico, Argentina – rising rates, PAHO/ALAD influence
Middle East & GulfHighest prevalence globally, government-backed initiatives

Tier 3

Long-Term Equity

Diet-first insights, low-cost detection, population prevention

AfricaFastest growth (+134% by 2045), 54% undiagnosed, limited CGM access
South-East Asia (non-India)Diverse diets, rapid urbanization, prevention opportunity

Cultural Dietary Context

Global nutrition guidance often fails by assuming Western norms. We account for staple foods (rice, maize, root-based diets), regional cooking methods, and cultural eating patterns.

Regulatory & Access Awareness

CGM and GLP-1 access varies widely by region. We reference regional regulatory authorities, recognizing that evidence-based recommendations must align with local policy and access constraints.

Read our full Global Health Strategy

Global Evidence

Research & Evidence Sources

Dietary Signals is informed by the latest global research and clinical guidelines. Below are the primary organizations and bodies whose recommendations, data, and peer-reviewed studies underpin our metabolic health guidance.

Global & Cross-Regional Authorities

Primary sources for worldwide prevalence data, meta-analyses, and cross-border policy frameworks.

World Health Organization (WHO) – Global policy, epidemiology, and public-health guidance Epidemiology
International Diabetes Federation (IDF) – Diabetes Atlas, global prevalence data, regional statistics Epidemiology
PubMed / NIH National Library of Medicine – Peer-reviewed metabolic-health research Clinical Guidance
Cochrane Library – Systematic reviews and meta-analyses of diet & glucose interventions Clinical Guidance

North America & Caribbean

Highest CGM adoption globally; GLP-1 widely available; FDA-cleared devices set global benchmarks.

United States

American Diabetes Association (ADA) – Standards of Medical Care, nutrition therapy, CGM use guidelines Clinical Guidance
CDC National Diabetes Statistics Report – U.S. prevalence, trends, economic burden Epidemiology
NIH / NIDDK – Clinical trials, basic science, patient resources Clinical Guidance
FDA – GLP-1 / Semaglutide safety and labeling Pharmacology
Endocrine Society – Clinical practice guidelines on obesity, GLP-1 agonists Pharmacology

Canada

Diabetes Canada – Clinical practice guidelines, nutrition best practices Clinical Guidance

Europe

Strong CGM reimbursement (NHS, EU); GLP-1 access varies by country; ADA-EASD consensus drives guidelines.

European Association for the Study of Diabetes (EASD) – ADA-EASD consensus statements, annual scientific sessions Clinical Guidance
IDF Europe – Region-specific policy and surveillance data Epidemiology
Diabetes UK – Evidence-based guides, research funding Clinical Guidance
Fédération Française des Diabétiques (France) Clinical Guidance
Deutsche Diabetes Gesellschaft (Germany) Clinical Guidance

South & Central America (LATAM)

BGM dominant; CGM limited to urban centers and private healthcare; GLP-1 availability varies; ALAD guidelines adapted for local diets.

IDF South & Central America – Regional prevalence, risk projections Epidemiology
ALAD (Asociación Latinoamericana de Diabetes) – Clinical guidelines, ALAD consensus documents Clinical Guidance
Sociedade Brasileira de Diabetes (Brazil) Clinical Guidance
Federación Mexicana de Diabetes Clinical Guidance

Middle East & North Africa (MENA)

Highest global prevalence (12.2%); BGM primary method; CGM growing in Gulf states only; Ramadan fasting guidelines critical.

IDF MENA – Highest regional prevalence globally; key surveillance data Epidemiology
Saudi Diabetes & Endocrine Association – National guidelines, clinical research Clinical Guidance
Egyptian Diabetes Association Clinical Guidance
Emirates Diabetes Society Clinical Guidance

South-East Asia

India = 101M with diabetes (world's largest); BGM/SMBG is primary monitoring method; CGM rare and expensive; GLP-1 access limited outside metros. Test strip affordability is a key barrier.

India (largest single country burden)

Regional

IDF South-East Asia – Bangladesh, Sri Lanka, Indonesia prevalence data Epidemiology
PERKENI (Indonesian Society of Endocrinology) Clinical Guidance

Western Pacific & East Asia

China = 140M+ (largest absolute burden), primarily BGM; Japan/Korea = higher CGM adoption (still minority); local device manufacturers emerging.

IDF Western Pacific – China (140+ million with diabetes), Japan, Korea data Epidemiology
Chinese Diabetes Society (CDS) – National clinical guidelines Clinical Guidance
Japan Diabetes Society – Evidence-based practice guidelines Clinical Guidance
Korean Diabetes Association Clinical Guidance

Australia & New Zealand

Strong PBS subsidies for CGM (Libre, Dexcom); GLP-1 covered; Pacific Islander populations have distinct risk profiles.

Diabetes Australia – National guidelines, AUSDIAB study Epidemiology
Diabetes New Zealand – Community programs, Pacific-islander health data Clinical Guidance
Baker Heart and Diabetes Institute – Research publications, clinical trials Clinical Guidance

Africa

Fastest-growing prevalence (+134% by 2045); 54% undiagnosed; BGM/test strip access is the critical gap; CGM essentially unavailable outside South Africa. Diet-first approaches essential.

Device & Market Research

Reality check: CGM is used by only ~1.5-2% of people with diabetes globally. BGM (blood glucose meters + test strips) remains the dominant monitoring method worldwide. Test strip affordability is a critical equity gap.

WHO – Access to Diabetes Diagnostics & Monitoring (BGM access gaps) Devices
Clinton Health Access Initiative – SMBG/BGM access in low/middle-income countries Devices
IDF Diabetes Atlas – Global monitoring access disparities Epidemiology
Mordor Intelligence – Blood Glucose Monitoring (BGM) Market Devices
Grand View Research – CGM Market Report (niche segment) Devices
Lancet Diabetes – Test strip access & affordability barriers Clinical Guidance
New England Journal of Medicine – GLP-1 / Semaglutide clinical trials Pharmacology

Why This Matters

Diabetes and metabolic dysfunction do not respect borders. With 537+ million people living with diabetes worldwide—and an estimated 1 in 2 undiagnosed—the need for accessible, evidence-based dietary guidance is global.

Dietary Signals synthesizes insights from these authoritative bodies to provide personalized, culturally-aware recommendations—whether you're managing glucose in Mumbai, Mexico City, or Melbourne.

This list is not exhaustive. We continuously monitor new research and regional updates to ensure our platform reflects the latest scientific consensus.